Assaf Raz

Assaf Raz has extensive experience in research and development, holding positions such as Vice President R&D at Phagelux Inc. and Precisio Biotix Therapeutics. Previously, Assaf worked as a Research Associate at Rockefeller University and as an Adjunct Assistant Professor at Hunter College. Assaf has a PhD in Microbiology from The Rockefeller University and a BA in Biology from Tel Aviv University. Assaf is known for leading a team that developed the lysibody technology, a fusion between a human IgG antibody and a carbohydrate-binding domain of bacterial or bacteriophage origin.